

**ADVANCEMENT OF RESEARCH FOR  
MYOPATHIES (ARM)**

FINANCIAL STATEMENTS  
AND  
AUDITORS' REPORT

SEPTEMBER 30, 2012

**ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)  
SEPTEMBER 30, 2012**

---

**TABLE OF CONTENTS**

	<u>PAGE</u>
INDEPENDENT AUDITORS' REPORT	1
FINANCIAL STATEMENTS	
Statement of Financial Position	2
Statement of Activities	3
Statement of Functional Expenses	4
Statement of Cash Flows	5
Notes to Financial Statements	6

# ALBERT DAVIDOO & ISAVI

*A Certified Public Accountancy Corporation*

## INDEPENDENT AUDITORS' REPORT

To the Board of Directors of  
Advancement of Research for Myopathies (ARM)  
Reseda, California

We have audited the accompanying statements of financial position of Advancement of Research for Myopathies - ARM (the "Organization") (a California non-profit Organization) as of September 30, 2012, and the related statements of activities, functional expenses, and cash flows for the year then ended. These financial statements are the responsibility of the Organization's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Advancement of Research for Myopathies - ARM as of September 30, 2012, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.



August 12, 2013

**ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)**  
Statement of Financial Position  
September 30, 2012

**ASSETS**

Current assets	
Cash	\$ <u>72,087</u>
Total current assets	72,087
Fixed assets	
Office equipment	401
Less accumulated depreciation	<u>401</u>
Total fixed assets	<u>-</u>
Total assets	<u>\$ 72,087</u>

**LIABILITIES AND NET ASSETS**

Current liabilities	
Grants payable	\$ 7,612
Accrued expenses	<u>6,651</u>
Total current liabilities	14,263
Contingencies	-
Net assets - Unrestricted	<u>57,824</u>
Total liabilities and net assets	<u>\$ 72,087</u>

The accompanying notes are an integral part of these financial statements.

**ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)**

Statement of Activities  
Year Ended September 30, 2012

**REVENUES:**

Contributions	<u>\$ 273,835</u>
Total revenues	273,835

**EXPENSES:**

Program services:	
Research development and patient services	50,612
Primary research	<u>101,005</u>
Total program services	151,617
Support services:	
General and administrative	7,193
Fundraising	<u>67,577</u>
Total support services	<u>74,770</u>
Total expenses	<u>226,387</u>
Increase in unrestricted net assets	47,448
Unrestricted net assets at beginning of year	<u>10,376</u>
Unrestricted net assets at end of year	<u>\$ 57,824</u>

The accompanying notes are an integral part of these financial statements.

**ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)**

Statement of Functional Expenses  
For the Year ended September 30, 2012

	<u>PROGRAM SERVICES</u>		<u>SUPPORT SERVICES</u>			
	<u>Program Services</u>	<u>Total Program Services</u>	<u>General and Administrative</u>	<u>Fund raising</u>	<u>Total Support Services</u>	<u>Total Expenses</u>
Grants and allocations	\$ 92,414	\$ 92,414	\$ -	\$ -	\$ -	\$ 92,414
Fund-raising activities	42,921	42,921	-	42,922	42,922	85,843
Other salaries and wages	13,000	13,000	-	13,000	13,000	26,000
Legal and professional fees	-	-	6,350	-	6,350	6,350
Credit card fees	-	-	-	4,838	4,838	4,838
Rent	-	-	474	4,263	4,737	4,737
Payroll taxes	1,212	1,212	-	1,211	1,211	2,423
Seminars	2,070	2,070	-	-	-	2,070
Office expenses	-	-	119	1,066	1,185	1,185
Postage and shipping	-	-	24	214	238	238
Bank fees	-	-	64	63	127	127
Dues and subscriptions	-	-	120	-	120	120
Licenses and permits	-	-	42	-	42	42
<b>Total</b>	<u>\$ 151,617</u>	<u>\$ 151,617</u>	<u>\$ 7,193</u>	<u>\$ 67,577</u>	<u>\$ 74,770</u>	<u>\$ 226,387</u>

The accompanying notes are an integral part of these financial statements.

**ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)**

Statement of Cash Flows

Year Ended September 30, 2012

CASH FLOWS FROM OPERATING ACTIVITIES:

Increase in unrestricted net assets	\$ 47,448
Adjustments to reconcile increase in unrestricted net assets to net cash provided by operating activities:	
Changes in assets and liabilities:	
Decrease in prepaid expenses	3,766
Increase in grants payable	7,612
Increase in accrued expenses	<u>3,485</u>
NET INCREASE IN CASH AND CASH EQUIVALENTS	62,311
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	<u>9,776</u>
CASH AND CASH EQUIVALENTS AT END OF YEAR	<u>\$ 72,087</u>

The accompanying notes are an integral part of these financial statements.

# ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)

Notes to Financial Statements

September 30, 2012

## NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### Nature of Activities

Advancement of Research for Myopathies (ARM) (the “Organization”) is a non-profit corporation organized to provide funds for development of effective treatments for autosomal recessive inclusion body myopathy (IBM2). IBM2 is also known as quadriceps spring myopathy (QSM), distal myopathy with rimmed vacuoles (DMRV or nonka’s myopathy), or hereditary inclusion body myopathy (HIBM).

### Basis of Accounting

The financial statements of Advancement of Research for Myopathies (ARM) have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles.

### Statement of Cash Flows

For the purposes of the statement of cash flows, the Organization considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

### Fixed Assets

Property and equipment are stated at cost. Depreciation on assets is provided for in amounts sufficient to relate the cost of depreciable assets to operations over their estimated service lives. The straight-line method of depreciation is followed for all assets.

### Income Taxes

Advancement of Research for Myopathies (ARM) is exempt from federal income taxes under Section 501 (c)(3) of the Internal Revenue Code and did not conduct unrelated business activities. Therefore, Advancement of Research for Myopathies (ARM) has made no provision for federal income taxes in the accompanying financial statements.

### Functional Allocation of Expenses

The costs of providing the various programs and other activities have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited.



## ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)

Notes to Financial Statements

September 30, 2012

### NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

#### Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

#### Restriction of Funds

All funds in the various bank accounts are unrestricted funds.

#### Evaluation of Subsequent Events

Management has evaluated subsequent events through August 12, 2013, the date that the financial statements were available to be issued.

### NOTE 2 – BASIS FOR GRANTS PAYABLE

Grants awards may extend a period of 1-3 years and are paid on a quarterly basis. The Organization records the initial year's liabilities and related expenses for the awarded grants after recommended for approval by the Organization's independent scientific peer reviewers and approved by the Board of Directors. Funding of the remaining committed future amounts of grants is contingent upon satisfactory scientific and/or medical review and the availability of funds. For the year ended September 30, 2012, \$50,612 in grants were paid to HIBM Research Group, Inc., which is a non-profit organization with the main purpose of engaging in medical research regarding Hereditary Inclusion Body Myopathies (HIBM).

### NOTE 3 – FUNDRAISING ACTIVITIES

Advancement of Research for Myopathies (ARM) organizes special events to increase awareness and raise funds for biomedical research.

## ADVANCEMENT OF RESEARCH FOR MYOPATHIES (ARM)

Notes to Financial Statements

September 30, 2012

### NOTE 4 – FIXED ASSETS

As of September 30, 2012, fixed assets consist of:

Office equipment	\$	401
Less accumulated depreciation		<u>401</u>
	\$	<u><u>-</u></u>

### NOTE 5 - COMMITMENTS

The Organization entered into a lease agreement for office space rental. The lease was to expire in June 2011 but was been extended to June 30, 2013. The organization relocated in June of 2013 and entered into a new lease agreement through June 30, 2014.

<u>YEAR</u>	<u>RENT EXPENSE</u>
2013	\$ 5,097
2014	4,275
2015	-
2016	-
2017	<u>-</u>
TOTAL	<u><u>\$ 9,372</u></u>

Total rent expense for the year was \$4,737.

### NOTE 6 – MAJOR CONTRIBUTIONS

During the year Advancement of Research for Myopathies (ARM) had contributions from two major donors (over \$ 5,000), representing 6% of the overall revenues.

### NOTE 7 - OFF-BALANCE SHEET CREDIT RISK

Advancement of Research for Myopathies (ARM) periodically maintains balances in its various cash accounts in excess of \$250,000. Such excess is not insured by the Federal Depository Insurance Corporation (FDIC).